GE Healthcare has completed the acquisition of Xcellerex, Inc., expanding its offering of technologies and services for the manufacture of biopharmaceuticals such as recombinant proteins, antibodies and vaccines.   Dr. Nigel Darby, vice president of BioTechnologies, and chief technology officer, GE Healthcare Life Sciences said, “Xcellerex’s expertise and reputation in technologies for biopharmaceutical manufacturing is a great fit with our business. GE and Xcellerex share a vision that an integ...